Purpose: To evaluate the effi cacy of intravitreal bevacizumab (IVB) in eyes with polypoidal choroidal vasculopathy (PCV).
Introduction
It is thought that vascular endothelial growth factor (VEGF) plays a central role in the formation and development of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). 1, 2 Visual prognosis in eyes with subfoveal CNV secondary to AMD is poor. A number of recent studies have reported promising results with bevacizumab (Avastin; Genentech, San Francisco, CA, USA), a recombinant humanized monoclonal antibody that binds to VEGF, for CNV secondary to AMD. 3 Polypoidal choroidal vasculopathy (PCV) was fi rst described as a new clinical entity with a unique form of choroidal vascular abnormality, characterized by a branching vascular network that terminates in polypoidal lesions seen on indocyanine green angiography. [4] [5] [6] However, Maruko et al. 7 reported that 5.5% of patients with exudative AMD showed PCV lesions in one eye and typical AMD lesions in the other. It is still controversial whether PCV is a distinct clinical entity or represents an aberrant form of AMD. 8 As in eyes with AMD, 9 VEGF concentrations in the aqueous humor are reported to be markedly increased in eyes with PCV. 10 The involvement of VEGF in the formation of PCV is also suggested by histologic specimens. 11 Therefore, anti-VEGF therapy may well be effective as a treatment for PCV.
Several investigators have reported the effects of intravitreal bevacizumab (IVB) as a treatment for exudative PCV.
persist after IVB injections, retinal thickness is reported to decrease shortly after the initiation of this treatment. [13] [14] [15] 17 In eyes with PCV, however, the effects of IVB on visual acuity (VA) remain controversial. [13] [14] [15] 17 In addition, because these studies had only a short follow-up period, limited information is available on the long-term effi cacy of IVB in eyes with PCV. 13 The present study was designed to study for at least 1 year the effects of IVB administered for treatment of PCV.
Material and Methods
For this interventional case series, we studied retrospectively the medical records of 17 eyes (16 patients) with active PCV that were treated with IVB at Kyoto University Hospital from October 2006 to April 2008. All eyes had a minimum follow-up period of 12 months after the initial treatment with IVB. The eligibility criteria were active PCV with a visual disturbance and treatment with IVB. The diagnosis of PCV was based on indocyanine green angiography results showing a branching vascular network that terminated in polypoidal swelling. In the current study, 15 eyes showed either a polypoidal lesion, a branching vascular network, or type 2 CNV beneath the center of the fovea. Two eyes showed a serous pigment epithelial detachment (PED) just beneath the fovea with adjacent juxtafoveal polypoidal lesions. Eyes with other macular abnormalities (i.e., AMD, pathologic myopia, idiopathic CNV, presumed ocular histoplasmosis, angioid streaks, or other secondary CNV) were excluded. In the present study, pseudophakic eyes were included, but eyes with a history of vitrectomy were excluded. Eyes that had undergone photodynamic therapy (PDT) for PCV within 4 months were also excluded. The study was approved by the Institutional Review Board at Kyoto University Graduate School of Medicine and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from each patient.
In the study described herein, patients who had a subjective visual disturbance due to subfoveal or juxtafoveal PCV were injected with IVB (1.25 mg/0.05 ml per injection). All injections were performed in a sterile manner and prophylactic topical antibiotics were applied for 1 week after injection. As the initial treatment, ten eyes were treated with a single injection of bevacizumab and seven were treated with three monthly injections. Each patient was scheduled to visit our clinic for an examination after a 1-2 month interval. After the initial treatment, when recurrent or residual exudative changes due to PCV were detected by either optical coherence tomography (OCT) or by a fundus examination, additional IVB injections were given.
At each visit, all patients underwent a comprehensive ophthalmologic examination, including best-corrected VA testing, intraocular pressure measurement, indirect ophthalmoscopy, slit-lamp biomicroscopy with a contact lens, fundus photography and OCT. Best-corrected VA was measured with a Landolt chart. Fluorescein and indocyanine green angiography were performed on each patient using a confocal laser scanning system (HRA-2; Heidelberg Engineering, Heidelberg, Germany) before and at 3-6 months after treatment. Additional angiography was performed as necessary.
In this study, spectral-domain OCT was used at the baseline examination and at follow-up visits. At each visit, all patients underwent examination by OCT of cross sections centered on the fovea as well as OCT of additional sections. Because eyes with PCV often show serosanguineous PED, foveal thickness was defi ned as the distance between the inner surface of the neurosensory retina and the thin straight line of Bruch's membrane. 14 All values are presented as means ± standard deviation. For statistical analysis, best-corrected VA measured with a Landolt chart was converted to a logarithm of the minimal angle of resolution (logMAR). A paired t test was used to evaluate changes in VA and foveal thickness. In each eye, VA was considered to be either improved or deteriorated when the change in VA (logMAR) was greater than 0.3. Statistical software (Statview 5.0; SAS Institute, Cary, NC, USA) was used for statistical analyses. A P value <0.05 was considered to be statistically signifi cant.
Results
In the current study, 17 eyes of 16 patients (14 men and two women), ranging in age from 60 to 85 years (74.8 ± 6.2 years), underwent IVB injections for the treatment of either subfoveal or juxtafoveal PCV (Table 1) . While three of the 17 eyes had undergone PDT previously, all eyes showed active exudative changes due to their PCV. No eyes had been treated previously with either local or systemic anti-VEGF therapy. Examination just before initiation of the IVB treatment showed polypoidal lesions in 14 eyes, branching vascular network in all 17 eyes, type 2 CNV in three eyes, serous retinal detachment in nine, and PED in ten eyes. Of the 17 eyes, subfoveal fi ndings were polypoidal lesions in four, a branching vascular network in 11, and PED in two eyes. Pretreatment VA on a Landolt chart ranged from 0.09 to 1.2 (median, 0.3); fi ve eyes had a VA better than 0.5 (median, 0.8) before treatment. Fifteen eyes received additional IVB injections. The total number of injections ranged from one to six (mean, 4.0 ± 1.7). Followup after the initiation of IVB ranged from 12 to 30 months (mean, 20.7 ± 5.7 months). Figure 1 shows the changes both in VA and in foveal thickness after IVB injection. IVB treatment reduced substantially the exudative changes after initiation of treatment in 13 eyes (Fig. 2) . The mean foveal thickness (492 ± 205 μm before treatment) decreased signifi cantly to 384 ± 181 μm (P = 0.0008) at 3 months. After the successful initial treatment, however, six eyes showed a recurrence of the exudative changes (Fig. 3) . Repeated angiography confi rmed a recurrence of polypoidal lesions in two eyes. With additional IVB, foveal thickness at 12 months (392 ± 203 μm) reduced signifi cantly compared with pretreatment measurements of thickness (P = 0.0270). The mean VA before treatment (0.54 ± 0.38 in logMAR) also improved somewhat, 0.45 ± 0.32 (P = 0.156) at 3 months, but the difference was not statistically signifi cant. Unfortunately, the improvement in VA subsided thereafter. At 12 months, mean VA had returned to the pretreatment value (0.54 ± 0.39). At 12 months, two eyes showed a signifi cant improvement in VA and no eye showed a signifi cant decrease in VA. There was no signifi cant difference in changes in either the VA or of the foveal thickness, no matter whether the initial treatment was a single injection of IVB or 3 monthly IVB injections.
In the current study, 14 eyes showed polypoidal lesions just before treatment with IVB, while postoperative angiography showed the polypoidal lesions to have disappeared in nine eyes (Fig. 4) . In no eye, however, had the branching vascular network disappeared. In addition, three eyes showed type 2 CNV just before the initiation of IVB. On postoperative angiography, leakage from the type 2 CNV had disappeared completely in two eyes and decreased substantially in the other eye. Figure 5 shows the changes in VA and in foveal thickness after IVB in fi ve eyes that had a good initial VA (better than 0.5 on a Landolt chart). The exudative change was reduced after the initiation of IVB treatment in all fi ve eyes, and after this successful initial treatment, recurrent exudative change or macular edema were treated with additional IVB injections. The mean VA (0.10 ± 0.11 in logMAR before treatment) was maintained at 12 months (0.13 ± 0.12) in all fi ve eyes; one, however, developed a tear of the retinal pigment epithelium at 3 months after 3 monthly IVB injections (Fig. 6 ).
Discussion
PCV is thought to have a better visual prognosis than AMD. 20 However, when the abnormal choroidal vasculature with exudative changes extends to the subfoveal area, visual prognosis is usually poor. Direct laser photocoagulation has been applied to eyes with PCV. 21 However, unless the entire lesion, including the polypoidal lesion and branching vascular network, is successfully coagulated, polypoidal lesion and exudative changes often recur, resulting in decreased VA. 22 A number of studies, however, have shown encouraging results of PDT for PCV. [23] [24] [25] According to Chan et al., 23 PDT resulted in either stable or improved VA in 95% of eyes with PCV 1 year after treatment. However, recent studies have shown that visual prognosis of PCV treated with PDT is not so promising. [26] [27] [28] One or more years after successful treatment with PDT, some eyes have a recurrence of PCV and, consequently, a decrease in VA.
Similar to AMD, some reports suggest that VEGF is involved in the development of vascular lesions in eyes with PCV. 10, 11 Several investigators have reported short-term effects of anti-VEGF therapy for the treatment of exudative PCV. [12] [13] [14] [15] [16] [17] [18] [19] 29 Ghajarnia et al. 12 fi rst reported a case of refractory PCV that was successfully treated with a single injection of IVB. Most subsequent reports have shown that IVB reduces the exudative changes resulting from PCV lesions Table 1 shortly after the initiation of treatment, while also exerting an effect on the vascular lesions of PCV. [13] [14] [15] 17 However, its effect on VA remains controversial. [13] [14] [15] 17 Gomi et al. 14 reported no improvement in VA at 3 months after treatment of PCV with IVB. On the other hand, Lai et al. 13 and Song et al. 15 reported a signifi cant improvement in VA at 3 months. However, because each of these studies included only a small number of patients, patient selection may have infl uenced the reported effi cacy of treatment. [13] [14] [15] 17 In addition, because each of these studies had a relatively short follow-up, 14 ,15,17 the long-term effects of IVB on eyes with PCV remains uncertain.
In the current study, follow-up after the initiation of IVB treatment was at least 12 months (mean, 20.7 ± 5.7 months). Similar to the previous studies, IVB treatment reduced the exudative changes substantially at 3 months, 13, 15, 17 and with additional IVB treating recurrent exudative changes, the decreased foveal thickness could be maintained for 12 months. With IVB, mean VA also somewhat improved at 3 months. This improvement in VA then subsided, and the mean VA returned to the pretreatment level at 12 months, even though the recurrent exudative changes were often treated successfully with additional IVB. Judging from the current study results, eyes with PCV that are treated with IVB can be expected to maintain the pretreatment VA for at least 1 year.
After the initial IVB treatment, our patients received additional IVB whenever a recurrent or persistent exudative change was seen. In both the MARINA 30 and ANCHOR 31 studies, monthly treatments with ranibizumab successfully improved the VA in eyes with AMD, while the PIER study 32 showed that less frequent scheduled injections did not maintain the improvement in VA that was obtained with the initial monthly injections. However, it is still controversial whether additional treatment with ranibizumab in response to recurrent or persistent exudative changes does maintain the improvement in VA achieved with the initial treatment. 33 The PrONTO study 33 showed a promising effect, although the SAILOR study did not. Even with additional IVB, our patients did not continue to show at the fi nal visit the VA improvement that they had gained at 3 months. Delayed treatment for the recurred exudative changes may damage the photoreceptor cells, resulting in poor visual outcome. It is possible that more frequent IVB . D Indocyanine green angiography reveals a branching vascular network terminating in two polypoidal lesions (arrow) and type 2 CNV (long arrow). This eye was treated with three monthly injections of bevacizumab and three additional injections. E Twenty-four months after the initial treatment, funduscopic photograph shows fi brosis and surrounding atrophy of retinal pigment epithelium. VA remained 0.15. F Horizontal (upper) and vertical (lower) optical coherence tomographic images along the white arrows in the fundus photograph (E) reveal minimal exudative changes with a protrusion of retinal pigment epithelium. G Fluorescein angiography shows minimal leakage. H Indocyanine green angiography reveals disappearance of both the polypoidal lesions and the type 2 CNV, but the branching vascular network is still visible.
injections might result in more promising fi nal VA. In addition, while our patients were scheduled to visit our clinic for an examination at a 1-2 month intervals, monthly examinations are expected to be essential to improve visual prognosis.
In the current study, IVB did result in regression of type 2 CNV secondary to PCV. In 36% of the eyes, however, the polypoidal lesions did not disappear with IVB, and the branching vascular network did not diminish at all. Why IVB was less effective against the PCV lesions themselves is uncertain. One possible explanation is the location of the vascular lesions of PCV, beneath the retinal pigment epithelium. 8 Another reason may be that VEGF is less involved in the vascular components of PCV than it is in CNV secondary to AMD. In light of the visual prognosis of eyes with PCV that received other treatments (i.e., laser photocoagulation or PDT), the recurrence of the vascular lesion may be the most crucial for the long-term treatment effect on PCV. 22, [26] [27] [28] In PCV, repeated treatment with IVB may be necessary to avoid recurrence. Furthermore, combination therapy with PDT might be superior to IVB monotherapy in order to reduce recurrence. 16, 18 The current study included fi ve eyes with relatively good initial VA (better than 0.5 on a Landolt chart), but as all these eyes showed exudative changes with subfoveal or juxtafoveal PCV, their visual prognosis might be poor in the absence of treatment. PDT may cause severe hemorrhagic complications in eyes with PCV, 34 and, in a clinical setting, it may be diffi cult to treat with PDT those eyes that have PCV and good VA. In eyes with PCV, IVB might be safer than PDT. Previously, Gomi et al. 14 used IVB in eyes with PCV that had good VA and maintained the initial VA for 3 months. In the current study in which IVB was used, all fi ve eyes with good initial VA maintained their VA for 12 months. However, one of these fi ve eyes developed a tear in the retinal pigment epithelium. Eyes with PCV often show a serosanguineous PED, 35 and when a large PED is seen beneath the fovea, it should be kept in mind that development of a tear in the retinal pigment epithelium is a possible complication of IVB. 36 Limitations of the current study are the various treatment regimens used and the small sample size. However, despite these shortcomings, our fi ndings suggest that IVB can maintain VA for at least 12 months in eyes with PCV. In addition, Reche-Frutos et al. 29 reported promising shortterm effects of ranibizumab for PCV, and anti-VEGF therapy also remains an option for the treatment of PCV. Therefore, prospective studies with long-term follow-up are needed to evaluate the safety and effi cacy of IVB for the treatment of PCV. 2. B Fluorescein angiography shows hyperfl uorescence refl ecting the PED. C Indocyanine green angiography reveals a branching vascular network terminating in two polypoidal lesions (arrows) at the edge of the PED. D Horizontal (left) and vertical (right) optical coherence tomographic images along the white arrows in the fundus photograph (A) show a sharp protrusion of the retinal pigment epithelium due to a polypoidal lesion (arrow) at the edge of the PED. The eye was treated with three monthly injections of bevacizumab. E Three months after the initial treatment, funduscopic examination shows a large tear of the RPE (arrowheads). VA decreased to 0.8. F Fluorescein angiography shows a window defect due to the tear of the RPE. G No polypoidal lesions are seen on indocyanine green angiography. Folded RPE shows a blockage of the fl uorescence (arrow). H Horizontal (left) and vertical (right) optical coherence tomographic images along the white arrows in the fundus photograph (E) reveal increased choroidal fl uorescence due to a lack of RPE (arrowheads). At 12 months, VA decreased to 0.4.
